Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded β-thalassemia/HbE patients treated with an oral chelator

Blood

Volumn 104, Issue 5, 2004, Pages 1504-1510

  Pootrakul, Pensri ^b   Breuer, William ^b   Sametband, Matias ^b   Sirankapracha, Pornpan ^b   Hershko, Chaim ^b   Cabantchik, Z Ioav ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; DEFERIPRONE; DEFEROXAMINE; HEMOGLOBIN E; IRON; TRANSFERRIN;

ARTICLE; BETA THALASSEMIA; CLINICAL ARTICLE; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; HEMOGLOBIN E DISEASE; HEMOGLOBINOPATHY; HUMAN; IRON BLOOD LEVEL; IRON OVERLOAD; LONG TERM CARE; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME;

EID: 4444274916     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-02-0630     Document Type: Article

References (29)

1. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood. 2000;95:1229-1236.
2. Miskin H, Yaniv I, Berant M, Hershko C, Tamary H. Reversal of cardiac complications in thalassaemia major by long-term intermittent daily intensive iron chelation. Eur J Haematol. 2003;70:398-403.
3. Kontoghiorghes GJ. Clinical use, therapeutic aspects and future potential of deferiprone in thalassemia and other conditions of iron and other metal toxicity. Drugs Today (Barc). 2001;37:23-35.
4. Barman Balfour JA, Foster RH. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases. Drugs. 1999;58:553-578.
5. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood. 2003;102:17-24.
6. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol. 1998;103:361-364.
7. Rombos Y, Tzanetea R, Konstantopoulos K, et al. Chelation therapy in patients with thalassaemia using the orally active iron chelator deferiprone (L1). Haematologica. 2000;85:115-117.
8. Olivieri NF, Koren G, Matsui D, et al. Reduction of tissue iron stores and normalization of serum ferritin during drug treatment with the oral iron chelator L1 in thalassemia intermedia. Blood. 1992;79:2741-2748.
9. Pootrakul P, Sirankapracha P, Sankote J, et al. Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand. Br J Haematol. 2003;122:305-310.
10. Breuer W, Hershko C, Cabantchik ZI. The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus Sci. 2000;23:185-192.
11. Breuer W, Ermers MJJ, Pootrakul P, Abramov A, Hershko C, Cabantchik ZI. Desferrioxamin-chelatable iron (DCI), a component of serum non-transferrin iron (NTBI) used for assessing iron chelation therapy. Blood. 2001;97:792-798.
12. Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood. 2003;102:2670-2677.
13. Torrance JD, Bothwell TH. A simple technique for measuring storage iron concentrations in formalinised liver samples. S Afr J Med Sci. 1968;33:9-11.
14. Repka T, Shalev O, Reddy R, et al. Nonrandom association of free iron with membranes of sickle and beta-thalassemic erythrocytes. Blood. 1993;82:3204-3210.
15. Browne PV, Shalev O, Kuypers FA, et al. Removal of erythrocyte membrane iron in vivo ameliorates the pathobiology of murine thalassaemia. J Clin Invest. 1997;100:1459-1464.
16. Flowers CA, Kuizon M, Beard JL, Skikne BS, Covell AM, Cook JD. A serum ferritin assay for prevalence studies of iron deficiency. Am J Hematol. 1986;23:141-151.
17. ICSH. Recommendations for measurement of serum iron in human blood. Br J Haematol. 1978;38:291-294.
18. Hershko C, Graham G, Bates GW, Rachmilewitz EA. Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol. 1978;40:255-263.
19. Gosriwatana I, Loreal O, Lu S, Brissot P, Porter J, Hider RC. Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin. Anal Biochem. 1999;273:212-220.
20. Breuer W, Cabantchik ZI. A fluorescence-based one-step assay for serum non-transferrin-bound iron. Anal Biochem. 2001;299:194-202.
21. Gutteridge JM, Rowley DA, Halliwell B. Superoxide-dependent formation of hydroxyl radicals in the presence of iron salts. Detection of 'free' iron in biological systems by using bleomycin-dependent degradation of DNA. Biochem J. 1981;199:263-265.
22. al-Refaie FN, Wickens DG, Wonke B, Kontoghiorghes GJ, Hoffbrand AV. Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1. Br J Haematol. 1992;82:431-436.
23. Porter JB, Abeysinghe RD, Marshall L, Hider RC, Singh S. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood. 1996;88:705-710.
24. Grootveld M, Bell JD, Halliwell B, Aruoma OI, Bomford A, Sadler PJ. Non-transferrin-bound iron in plasma or serum from patients with idiopathic hemochromatosis. Characterization by high performance liquid chromatography and nuclear magnetic resonance spectroscopy. J Biol Chem. 1989;264:4417-4422.
25. Hider RC. Nature of nontransferrin-bound iron. Eur J Clin Invest. 2002;32(suppl 1):50-54.
26. al-Refaie FN, Sheppard LN, Nortey P, Wonke B, Hoffbrand AV, Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload. Br J Haematol. 1995;89:403-408.
27. Brittenham GM, Sheth S, Allen CJ, Farrell DE. Noninvasive methods for quantitative assessment of transfusional iron overload in sickle cell disease. Semin Hematol. 2001;38(suppl 1):37-56.
28. Fischer R, Longo F, Nielsen P, Engelhardt R, Hider RC, Piga A. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br J Haematol. 2003;121:938-948.
29. Jensen PD, Jensen FT, Christensen T, Eiskjaer H, Baandrup U, Nielsen JL. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood. 2003;101:4632-4639.